FibroGen Statistics
Total Valuation
FibroGen has a market cap or net worth of $30.86 million. The enterprise value is $70.55 million.
Important Dates
The last earnings date was Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
FibroGen has 101.04 million shares outstanding. The number of shares has increased by 2.82% in one year.
| Current Share Class | 101.04M |
| Shares Outstanding | 101.04M |
| Shares Change (YoY) | +2.82% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 1.50% |
| Owned by Institutions (%) | 27.68% |
| Float | 92.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.04 |
| Forward PS | 0.20 |
| PB Ratio | -0.17 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.47
| Current Ratio | 1.47 |
| Quick Ratio | 0.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.88 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -25.66% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -161.25% |
| Revenue Per Employee | $131,649 |
| Profits Per Employee | -$211,462 |
| Employee Count | 225 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 10.95 |
Taxes
| Income Tax | -269,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.67% in the last 52 weeks. The beta is 0.87, so FibroGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -73.67% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 0.42 |
| Relative Strength Index (RSI) | 46.11 |
| Average Volume (20 Days) | 555,545 |
Short Selling Information
The latest short interest is 3.76 million, so 3.72% of the outstanding shares have been sold short.
| Short Interest | 3.76M |
| Short Previous Month | 4.18M |
| Short % of Shares Out | 3.72% |
| Short % of Float | 4.05% |
| Short Ratio (days to cover) | 3.08 |
Income Statement
In the last 12 months, FibroGen had revenue of $29.62 million and -$47.58 million in losses. Loss per share was -$0.48.
| Revenue | 29.62M |
| Gross Profit | -81.63M |
| Operating Income | -130.96M |
| Pretax Income | -168.39M |
| Net Income | -47.58M |
| EBITDA | -128.27M |
| EBIT | -130.96M |
| Loss Per Share | -$0.48 |
Full Income StatementBalance Sheet
The company has $50.48 million in cash and $90.17 million in debt, giving a net cash position of -$39.69 million or -$0.39 per share.
| Cash & Cash Equivalents | 50.48M |
| Total Debt | 90.17M |
| Net Cash | -39.69M |
| Net Cash Per Share | -$0.39 |
| Equity (Book Value) | -183.64M |
| Book Value Per Share | -2.24 |
| Working Capital | 63.20M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$138.00 million and capital expenditures -$266,000, giving a free cash flow of -$138.27 million.
| Operating Cash Flow | -138.00M |
| Capital Expenditures | -266,000 |
| Free Cash Flow | -138.27M |
| FCF Per Share | -$1.37 |
Full Cash Flow StatementMargins
Gross margin is -275.59%, with operating and profit margins of -442.13% and -160.63%.
| Gross Margin | -275.59% |
| Operating Margin | -442.13% |
| Pretax Margin | -517.76% |
| Profit Margin | -160.63% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FibroGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.82% |
| Shareholder Yield | -2.82% |
| Earnings Yield | -154.18% |
| FCF Yield | -448.06% |
Analyst Forecast
The average price target for FibroGen is $10.00, which is 3,174.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 3,174.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 74.68% |
| EPS Growth Forecast (5Y) | -1.44% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FibroGen has an Altman Z-Score of -13.71 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.71 |
| Piotroski F-Score | 2 |